Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Transcript

Why It Matters

The results underscore Gilead's ability to grow its core HIV and liver businesses despite pricing pressures, while signaling diversification through new launches that could offset slowing cell‑therapy sales. Strong cash returns and a robust pipeline position the company for continued shareholder value creation.

Key Takeaways

• Total sales $28.9B, modest 1% growth, beat guidance
• HIV revenue $20.8B, 6% growth, 10% underlying without Part D
• YES2GO reached 90% payer coverage, $800M 2026 target
• Cell therapy revenue down 7%, further decline expected 2026
• Four 2026 launches diversify HIV, oncology, hepatitis portfolio

Pulse Analysis

Gilead Sciences' 2025 earnings paint a picture of steady, if modest, top‑line expansion anchored by its HIV and liver franchises. Total product sales rose to $28.9 billion, edging past the upper end of guidance and delivering a 45% non‑GAAP operating margin. The company’s disciplined expense management—SG&A down 5% and R&D flat—helped sustain an EPS of $8.15, while returning 63% of free cash flow to shareholders through dividends and buybacks. Analysts view this financial footing as a solid platform for the next wave of growth.

The HIV portfolio remains the engine of Gilead's performance, with $20.8 billion in revenue and a 6% year‑over‑year increase that masks a 10% underlying rise once the Part D redesign impact is stripped out. Flagship products Biktarvy and Descovy continued to gain market share, the former holding over 52% of U.S. prescriptions. The recently launched YES2GO injectable achieved 90% payer coverage ahead of schedule, and management projects $800 million in 2026 sales, positioning it as a potential blockbuster in HIV prevention. However, a roughly 2% growth headwind from new drug‑pricing agreements and ACA changes could temper future gains.

Looking ahead, Gilead is betting on diversification to offset the 7% decline in cell‑therapy revenue and anticipated 10% dip in 2026. Four new launches—Trodelvy for first‑line metastatic triple‑negative breast cancer, Viclen (a bictegravir‑lenacapavir combo) for HIV, Anidocel for multiple myeloma, and bruleviratide for hepatitis delta—expand its addressable market across three therapeutic pillars. Coupled with five Phase III readouts and five FDA decisions slated for 2026, the pipeline promises to sustain growth momentum. While competitive pressure in cell therapy and payer policy pose risks, the company’s strong cash generation and shareholder‑return track record provide a buffer as it executes its diversification strategy.